 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- pimicotinib (ABSK021) / Abbisko, EMD Serono, Conmana (icotinib) / Betta Pharma
CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRASG12C inhibitors in preclinical non-small cell lung cancer mouse models (Section 54) - Mar 5, 2024 - Abstract #AACR2024AACR_2184;
Abstract is embargoed at this time.
- ABSK071 / Abbisko
A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models (Section 35; Poster Board #7) - Mar 14, 2023 - Abstract #AACR2023AACR_8004;
ABSK071 is a next-generation KRASG12C inhibitor with greater activity and anti-tumor efficacy in vitro and in vivo. It also demonstrated broad synergistic effects with a large set of targeted agents and immuno-oncology agents, indicating its strong potential in combinatory therapy in treating a wider range of KRASG12C-dependent cancers.
- ABSK071 / Abbisko
Discovery and characterization of ABSK071, a novel and potent small-molecule covalent inhibitor for KRAS-G12C (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_218;
In vivo efficacy studies showed that ABSK071 has higher anti-tumor potency than sotorasib at the same dose in multiple xenograft models. Together, these data demonstrated the antitumor activity of ABSK071 towards KRASG12C-dependent cancers.